Loading stock data…
Wave Life Sciences Ltd. (WVE)
$4.91+0.05 (+1.03%)
Market ClosedLast close Sep 8
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Wave Life Sciences Ltd. in the Healthcare sector is trading at $4.91 with a market capitalization of $1.2B. Wall Street consensus targets $19.06 (16 analysts), implying a +288.2% move over the next 12 months. The stock is currently near its 52-week low of $4.65, remaining 47.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +288.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.27M↓ | $38.25M↑ | $17.25M↑ | $7.61M↓ | $8.70M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$73.80M↓ | -$31.30M↑ | -$56.47M↓ | -$56.35M↓ | -$52.76M |
| Net Income | -$69.36M↓ | -$26.09M↑ | -$53.18M↑ | -$53.85M↓ | -$50.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.64%
Volume
Today's trading volume
3.53M
Recent News
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.
Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?
Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.
Wave Life Sciences Ltd. Q2 2026 Earnings Call Summary
Moby summary of Wave Life Sciences Ltd.'s Q2 2026 earnings call
WAVE Life Sciences Q2 Earnings Call Highlights
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026. The company reported second-quarter revenue of $2.3 million, down